News

As Shanghai re-emerges from a Covid-19 outbreak and three years of restrictions that hampered travel and trade, the financial hub is doing so without much evidence of what made it China’s most cosmopolitan city: foreign visitors. Before the pandemic, its iconic Bund was usually thronged with foreign travellers and business delegations. But on a recent
0 Comments
Several of the world’s biggest pharmaceutical companies are fighting shareholder proposals to force them to disclose information on their use of a controversial patent strategy that can delay rivals from launching cheaper versions of blockbuster drugs. A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers
0 Comments
For years, Austria’s Raiffeisen Bank vaunted its staying power in Russia as western rivals came and went. “Russia,” Raiffeisen’s former chief executive Herbert Stepic liked to say, “separates the wheat from the chaff”. Now, the situation is reversed. One year into Russia’s bloody invasion of Ukraine, as western companies flee the country, fearful of the
0 Comments
HM Revenue & Customs has launched a crackdown on the booming short-term lettings market by initially targeting about 1,000 property owners that it suspects have not paid enough tax. Based on information received from online bookings platforms such as Airbnb, the UK tax agency is sending its first so-called “nudge” letters this month to those
0 Comments
Russia’s invasion of Ukraine a year ago reverberated through global markets. With no end in sight to Europe’s most intense conflict since the second world war, the effects are still being felt. Financial Times reporters look at what has occurred in key markets and what might happen next. Putin’s energy war backfires Running almost in
0 Comments
When the US drugs company Abbott Laboratories acquired a small division of the German chemicals group BASF for $6.9bn 23 years ago, its shares fell on fears that it had overpaid. But the deal was an amazing bargain. Humira, the promising medicine that came with it, is now the industry’s biggest blockbuster, with cumulative revenues
0 Comments